UTHR's ralinepag NDA receives FDA acceptance, with a 2027 decision ahead as positive phase III data

Up to 12,853,470 SharesCommon StockThis prospectus supplement relates to the offer and resale by the

Three revenue streams continue to feed modest growth for MannKind. Two new FDA approvals show promis

Wells Fargo analyst Benjamin Burnett maintains MannKind (NASDAQ:MNKD) with a Overweight and lower

MannKind Corporation (MNKD) Q2 2026 Earnings Call Transcript

MannKind NASDAQ: MNKD reported second-quarter revenue of $109.4 million, up 43% from the prior-year

The headline numbers for MannKind (MNKD) give insight into how the company performed in the quarter

MannKind (MNKD) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimat

MannKind (NASDAQ:MNKD) reported quarterly losses of $(0.01) per share which missed the analyst conse

Achieved three major catalysts to drive future growth: Launched the pediatric indication of Afrezza

MannKind Corporation (MNKD) Discusses Phase 1b Results and Clinical Progress of Nintedanib DPI for I

Wells Fargo analyst Benjamin Burnett maintains MannKind (NASDAQ:MNKD) with a Overweight and raise

MannKind NASDAQ: MNKD reported Phase 1b results for its inhaled nintedanib dry-powder inhalation, or

We also report on an experimental diagnostic approach that can ​detect tuberculosis exposure and inf

Generally well-tolerated with no serious adverse events, bronchospasm or diarrhea; no study drug dis

MNKD Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety & Tolerability of Nintedanib DP

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation

MannKind Corporation (NASDAQ: MNKD - Get Free Report)'s stock price gapped up prior to trading on Fr

Mannkind Corporation (NASDAQ:MNKD) shares are trading higher as the company recently announced the U

MannKind stock rose after the FDA approved Furoscix ReadyFlow, as the company also announced a $50 m

MannKind Corporation (MNKD) Discusses FDA Approval of Furoscix ReadyFlow for IV-Equivalent Diuretic

MannKind NASDAQ: MNKD said the U.S. Food and Drug Administration approved Furoscix ReadyFlow, an aut

MannKind Corporation (NASDAQ:MNKD), a biopharmaceutical company dedicated to transforming chronic di

DANBURY, Conn. and WESTLAKE VILLAGE, Calif.

Furoscix ReadyFlow is an at-home treatment option designed to help adults with heart failure or chro

MannKind announces FDA approval of Furoscix ReadyFlow™, the first & only autoinjector delivering IV-

This MannKind insider filing details the disposition of 46,795 shares. The transaction reduced the i

The transactions involved 76,880 shares with a total value of about $313,000, based on a weighted av

Collaboration underscores interest in inhaled insulin and strengthens bringing innovation and new op

Builds on recent FDA approval (May 29, 2026) of Afrezza for use in children and adolescents aged 6 a

Cramer put Photronics in the penalty box due to poor results. He praised Woodward and warned against

MannKind Corporation (NASDAQ:MNKD), a biopharmaceutical company focused on developing innovative, pa

MannKind Corporation (NASDAQ:MNKD) announced today that management will host a conference call to di

Enables dosing at the start of a meal, offering flexibility for children and adolescents as they man

MannKind Corporation (NASDAQ:MNKD), a biopharmaceutical company dedicated to transforming chronic di

RBC Capital analyst Douglas Miehm maintains MannKind (NASDAQ:MNKD) with a Sector Perform and rais

Wells Fargo analyst Benjamin Burnett maintains MannKind (NASDAQ:MNKD) with a Overweight and raise

Mizuho analyst Anthony Petrone maintains MannKind (NASDAQ:MNKD) with a Outperform and lowers the

U.S. stock futures up, Dow futures gain 0.1% as Snap (NYSE: SNAP) shares fall 10.5%, Fastly (NASDAQ:

HC Wainwright & Co. analyst Brandon Folkes maintains MannKind (NASDAQ:MNKD) with a Buy and ra

MannKind (NASDAQ:MNKD) reported quarterly losses of $(0.02) per share which missed the analyst conse

Dow Jones up 500 points, DaVita Inc (DVA) shares rise after better-than-expected earnings and raised

The formulation is being developed in collaboration with United Therapeutics Corporation United Ther

Wells Fargo analyst Benjamin Burnett maintains MannKind (NASDAQ:MNKD) with a Overweight and raise

Wedbush analyst Yun Zhong maintains MannKind (NASDAQ:MNKD) with a Outperform and lowers the price

RBC Capital analyst Douglas Miehm downgrades MannKind (NASDAQ:MNKD) from Outperform to Sector Per